NextGen Healthcare, Inc. Reports Fiscal 2020 First Quarter Results

IRVINE, Calif.--()--NextGen Healthcare, Inc. (NASDAQ: NXGN), the leading provider of ambulatory-focused healthcare technology solutions, announced today its fiscal 2020 first quarter ended June 30, 2019 operating results.

Fiscal 2020 First Quarter Highlights

On a GAAP basis, revenue for the fiscal 2020 first quarter was $131.9 million compared to $133.2 million a year-ago.

On a GAAP basis, net income for the fiscal 2020 first quarter was $1.2 million, compared with net income of $2.6 million in the fiscal 2019 first quarter.

On a GAAP basis, fully diluted net income per share was $0.02 in the fiscal 2020 first quarter compared to net income per share of $0.04 per share for the same period a year ago. On a non-GAAP basis, fully diluted earnings per share for the fiscal 2020 first quarter was $0.16 versus $0.19 reported in the first quarter a year ago.

Cash flow from operations was $17.0 million in the fiscal 2020 first quarter compared to $3.0 million for the same period a year ago. Free cash flow was $8.6 million compared to $3.9 million of cash used in the same period a year ago.

“In the first quarter of fiscal 2020, we took another sizeable step forward in terms of client satisfaction and realized bookings growth of 9%. Across the board, our financials came in mostly in line. While we did experience some trends in the quarter that will affect the full year revenue, the continued increase in the size of our deals and the launch of new capabilities support our confidence in our future growth plans,” said Rusty Frantz, president and chief executive officer of NextGen Healthcare.

Fiscal 2020 Financial Outlook

The company is updating their outlook for fiscal 2020 and now expects:

  • Revenue of between $536 million and $550 million
  • Non-GAAP EPS of between $0.82 and $0.90

Conference Call Information

NextGen Healthcare will host a conference call to discuss its fiscal 2020 first quarter operating results on Wednesday, July 24, 2019 at 5:00 PM ET (2:00 PM PT). Shareholders and interested participants may listen to a live broadcast of the conference call by dialing 866-750-8947 or 720-405-1352 for international callers, and referencing participant code 4939527 approximately 15 minutes prior to the call. A recording of the live webcast will be available on investor.nextgen.com after the call. It will be archived for 90 days until October 23, 2019.

About NextGen Healthcare, Inc

NextGen Healthcare is enabling the transformation of ambulatory care by providing a range of software, services, and analytics solutions to medical and dental group practices. The company's portfolio delivers foundational capabilities to empower physician success, enrich the patient care experience, and enable the transition to value-based healthcare. Visit www.nextgen.com for additional information.

SAFE HARBOR PROVISIONS FOR FORWARD-LOOKING STATEMENTS

This news release may contain forward-looking statements within the meaning of the federal securities laws, including but not limited to, statements regarding future events, developments in the healthcare sector and regulatory framework, the Company's future performance, as well as management's expectations, beliefs, intentions, plans, estimates or projections relating to the future (including, without limitation, statements concerning revenue, net income, and earnings per share). Risks and uncertainties exist that may cause the results to differ materially from those set forth in these forward-looking statements. Factors that could cause the anticipated results to differ from those described in the forward-looking statements and additional risks and uncertainties are set forth in Part I, Item A of our most recent Annual Report on Form 10-K and subsequently filed Quarterly Reports on Form 10-Q, including but not limited to: the volume and timing of systems sales and installations; length of sales cycles and the installation process; the possibility that products will not achieve or sustain market acceptance; seasonal patterns of sales and customer buying behavior; impact of incentive payments under The American Recovery and Reinvestment Act on sales and the ability of the Company to meet continued certification requirements; uncertainties related to the future impact of U.S. tax reform; the impact of governmental and regulatory agency investigations; the development by competitors of new or superior technologies; the timing, cost and success or failure of new product and service introductions, development and product upgrade releases; undetected errors or bugs in software; product liability; changing economic, political or regulatory influences in the health-care industry; changes in product-pricing policies; availability of third-party products and components; competitive pressures including product offerings, pricing and promotional activities; the Company's ability or inability to attract and retain qualified personnel; possible regulation of the Company's software by the U.S. Food and Drug Administration; changes of accounting estimates and assumptions used to prepare the prior periods' financial statements; disruptions caused by acquisitions of companies, products, or technologies; and general economic conditions. A significant portion of the Company's quarterly sales of software product licenses and computer hardware is concluded in the last month of a fiscal quarter, generally with a concentration of such revenues earned in the final ten business days of that month. Due to these and other factors, the Company's revenues and operating results are very difficult to forecast. A major portion of the Company's costs and expenses, such as personnel and facilities, are of a fixed nature and, accordingly, a shortfall or decline in quarterly and/or annual revenues typically results in lower profitability or losses. As a result, comparison of the Company's period-to-period financial performance is not necessarily meaningful and should not be relied upon as an indicator of future performance. These forward-looking statements speak only as of the date hereof. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

USE OF NON-GAAP FINANCIAL MEASURES

This news release contains certain non-GAAP (Generally Accepted Accounting Principles) financial measures, which are provided only as supplemental information. Investors should consider these non-GAAP financial measures only in conjunction with the comparable GAAP financial measures. These non-GAAP measures are not in accordance with or a substitute for U.S. GAAP. Pursuant to the requirements of Regulation G, the Company has provided a reconciliation of non-GAAP financial measures to the most directly comparable financial measure in the accompanying financial tables. Other companies may calculate non-GAAP measures differently than NextGen Healthcare, Inc., which limits comparability between companies. The Company believes that its presentation of non-GAAP diluted earnings per share provides useful supplemental information to investors and management regarding the Company's financial condition and results. The presentation of non-GAAP financial information is not intended to be considered in isolation or as a substitute for, or superior to, financial information prepared and presented in accordance with GAAP. The Company calculates free cash flow by as total Net cash provided by operating activities, net of cash used for the additions of capitalized software costs and equipment and improvements. The Company calculates non-GAAP diluted earnings per share by excluding net acquisition costs, amortization of acquired intangible assets, amortization of deferred debt issuance costs, restructuring costs, net securities litigation defense costs, share-based compensation, impairment of assets, and other non-run-rate expenses from GAAP income before provision for income taxes.

The Company utilizes a normalized non-GAAP tax rate to provide better consistency across the interim reporting periods within a given fiscal year by eliminating the effects of non-recurring and period-specific items, which can vary in size and frequency, and which are not necessarily reflective of the Company’s longer-term operations. The normalized non-GAAP tax rate applied to each quarter of fiscal year 2019 was 22.0% and is expected to remain at 22.0% for each quarter of fiscal year 2020. The determination of this rate is based on the consideration of both historic and projected financial results. The Company may adjust its non-GAAP tax rate as additional information becomes available and in conjunction with any other significant events occur that may materially affect this rate, such as merger and acquisition activity, changes in business outlook, or other changes in expectations regarding tax regulations.

The Company’s future period guidance in this release includes adjustments for items not indicative of the Company’s core operations. Such adjustments are generally expected to be of a nature similar to those adjustments applied to the Company’s historic GAAP financial results in the determination of the Company’s non-GAAP diluted earnings per share. Such adjustments, however, may be affected by changes in ongoing assumptions and judgments as to the items that are excluded in the calculation of non-GAAP adjusted net income and adjusted diluted earnings per share, as described in this release. The exact amount and probable significance of these adjustments, including net acquisition costs, restructuring costs, net securities litigation defense costs, impairment of assets, and other non-run-rate expenses, are not currently determinable without unreasonable efforts, but may be significant. These items cannot be reliably quantified or forecasted due to the combination of their historic and expected variability. It is therefore not practicable to reconcile this non-GAAP guidance to the most comparable GAAP measures.

NEXTGEN HEALTHCARE, INC.

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(In thousands, except per share data)

(Unaudited)

 

 

Three Months Ended June 30,

 

 

2019

 

 

2018

 

Revenues:

 

 

 

 

 

 

 

Recurring

$

119,447

 

 

$

120,007

 

Software, hardware, and other non-recurring

 

12,414

 

 

 

13,193

 

Total revenues

 

131,861

 

 

 

133,200

 

Cost of revenue:

 

 

 

 

 

 

 

Recurring

 

50,540

 

 

 

48,153

 

Software, hardware, and other non-recurring

 

6,278

 

 

 

7,154

 

Amortization of capitalized software costs and acquired intangible assets

 

8,413

 

 

 

6,544

 

Total cost of revenue

 

65,231

 

 

 

61,851

 

Gross profit

 

66,630

 

 

 

71,349

 

Operating expenses:

 

 

 

 

 

 

 

Selling, general and administrative

 

40,128

 

 

 

44,636

 

Research and development costs, net

 

22,051

 

 

 

22,128

 

Amortization of acquired intangible assets

 

865

 

 

 

1,168

 

Impairment of assets

 

489

 

 

 

 

Restructuring costs

 

1,707

 

 

 

 

Total operating expenses

 

65,240

 

 

 

67,932

 

Income from operations

 

1,390

 

 

 

3,417

 

Interest income

 

79

 

 

 

29

 

Interest expense

 

(472

)

 

 

(730

)

Other income (expense), net

 

(133

)

 

 

374

 

Income before provision for (benefit of) income taxes

 

864

 

 

 

3,090

 

Provision for (benefit of) income taxes

 

(380

)

 

 

442

 

Net income

$

1,244

 

 

$

2,648

 

Net income per share:

 

 

 

 

 

 

 

Basic

$

0.02

 

 

$

0.04

 

Diluted

$

0.02

 

 

$

0.04

 

Weighted-average shares outstanding:

 

 

 

 

 

 

 

Basic

 

65,015

 

 

 

64,019

 

Diluted

 

65,353

 

 

 

64,054

 

NEXTGEN HEALTHCARE, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except per share data)

(Unaudited)

 

 

 

June 30, 2019

 

 

March 31, 2019

 

ASSETS

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

28,607

 

 

$

33,079

 

Restricted cash and cash equivalents

 

 

8,183

 

 

 

1,443

 

Accounts receivable, net

 

 

81,748

 

 

 

87,459

 

Contract assets

 

 

12,039

 

 

 

13,242

 

Inventory

 

 

72

 

 

 

120

 

Income taxes receivable

 

 

2,882

 

 

 

3,682

 

Prepaid expenses and other current assets

 

 

21,985

 

 

 

20,826

 

Total current assets

 

 

155,516

 

 

 

159,851

 

Equipment and improvements, net

 

 

22,772

 

 

 

21,404

 

Capitalized software costs, net

 

 

38,465

 

 

 

37,855

 

Operating lease assets

 

 

41,992

 

 

 

 

Deferred income taxes, net

 

 

6,207

 

 

 

6,194

 

Contract assets, net of current

 

 

3,554

 

 

 

3,747

 

Intangibles, net

 

 

47,442

 

 

 

52,595

 

Goodwill

 

 

218,771

 

 

 

218,771

 

Other assets

 

 

32,606

 

 

 

32,478

 

Total assets

 

$

567,325

 

 

$

532,895

 

LIABILITIES AND SHAREHOLDERS' EQUITY

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Accounts payable

 

$

5,848

 

 

$

5,432

 

Contract liabilities

 

 

53,963

 

 

 

56,009

 

Accrued compensation and related benefits

 

 

17,226

 

 

 

25,663

 

Income taxes payable

 

 

57

 

 

 

64

 

Operating lease liabilities

 

 

9,744

 

 

 

 

Other current liabilities

 

 

41,412

 

 

 

41,064

 

Total current liabilities

 

 

128,250

 

 

 

128,232

 

Deferred compensation

 

 

6,046

 

 

 

5,905

 

Line of credit

 

 

6,000

 

 

 

11,000

 

Operating lease liabilities, net of current

 

 

44,281

 

 

 

 

Other noncurrent liabilities

 

 

1,918

 

 

 

11,812

 

Total liabilities

 

 

186,495

 

 

 

156,949

 

Commitments and contingencies

 

 

 

 

 

 

 

 

Shareholders' equity:

 

 

 

 

 

 

 

 

Common stock

 

 

 

 

 

 

 

 

$0.01 par value; authorized 100,000 shares; issued and outstanding 65,383 and 64,838 shares at June 30, 2019 and March 31, 2019, respectively

 

 

654

 

 

 

648

 

Additional paid-in capital

 

 

268,488

 

 

 

264,908

 

Accumulated other comprehensive loss

 

 

(1,177

)

 

 

(1,231

)

Retained earnings

 

 

112,865

 

 

 

111,621

 

Total shareholders' equity

 

 

380,830

 

 

 

375,946

 

Total liabilities and shareholders' equity

 

$

567,325

 

 

$

532,895

 

NEXTGEN HEALTHCARE, INC.

NON-GAAP FINANCIAL MEASURES

(In thousands, except per share data)

 

RECONCILIATION OF NON-GAAP DILUTED EARNINGS PER SHARE

 

 

Three Months Ended June 30,

 

 

2019

 

 

2018

 

Income before provision for income taxes - GAAP

$

864

 

 

$

3,090

 

Non-GAAP adjustments:

 

 

 

 

 

 

 

Acquisition costs, net

 

 

 

 

1,634

 

Amortization of acquired intangible assets

 

5,153

 

 

 

5,456

 

Amortization of deferred debt issuance costs

 

177

 

 

 

177

 

Restructuring costs

 

1,707

 

 

 

 

Securities litigation defense costs, net of insurance

 

37

 

 

 

279

 

Share-based compensation

 

4,891

 

 

 

3,116

 

Impairment of assets

 

489

 

 

 

 

Other non-run-rate expenses*

 

90

 

 

 

1,948

 

Total adjustments to GAAP income before provision for income taxes:

 

12,544

 

 

 

12,610

 

Income before provision for income taxes - Non-GAAP

 

13,408

 

 

 

15,700

 

Provision for income taxes

 

2,950

 

 

 

3,454

 

Net income - Non-GAAP

$

10,458

 

 

$

12,246

 

Diluted net income per share - Non-GAAP

$

0.16

 

 

$

0.19

 

Weighted-average shares outstanding (diluted):

 

65,353

 

 

 

64,054

 

* Other non-run-rate expenses for the three months ended June 30, 2019 consist primarily of excess lease-related expense for vacated locations. Other non-run-rate expenses for the three months ended June 30, 2018 consist primarily of severance and other employee-related costs not related to core operations.

 

Contacts

Media Contact:
NextGen Healthcare
Cynthia Ragland, (949) 255-2600 x75416
cragland@nextgen.com
or
Investor Contact:
Westwicke Partners
Bob East or Asher Dewhurst
Westwicke Partners
443-213-0500

Contacts

Media Contact:
NextGen Healthcare
Cynthia Ragland, (949) 255-2600 x75416
cragland@nextgen.com
or
Investor Contact:
Westwicke Partners
Bob East or Asher Dewhurst
Westwicke Partners
443-213-0500